19.83
+12.962(+188.73%)
Currency In USD
| Previous Close | 6.87 |
| Open | 10.54 |
| Day High | 26.99 |
| Day Low | 10.35 |
| 52-Week High | 896 |
| 52-Week Low | 6.71 |
| Volume | 57.37M |
| Average Volume | 101,355 |
| Market Cap | 10.23M |
| PE | -0.04 |
| EPS | -488.69 |
| Moving Average 50 Days | 12.55 |
| Moving Average 200 Days | 113.28 |
| Change | 12.96 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $1 as of June 17, 2025 at a share price of $19.83. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0.99 as of June 17, 2025 at a share price of $19.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
10 hours ago
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutic
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
GlobeNewswire Inc.
Jun 06, 2025 12:15 PM GMT
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagoc
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
GlobeNewswire Inc.
Jun 02, 2025 1:05 PM GMT
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”)